Molecular and Morphological Profiling of Lung Cancer: A Foundation for “Next-Generation” Pathologists and Oncologists
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular and Morphological Profiling of Lung Cancer: A Foundation for “Next-Generation” Pathologists and Oncologists
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 5, Pages 599
Publisher
MDPI AG
Online
2019-04-29
DOI
10.3390/cancers11050599
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer
- (2018) Yusuke Okuma et al. Clinical Lung Cancer
- Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling
- (2018) Alexander S. Baras et al. Journal of the National Comprehensive Cancer Network
- Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: implications for differential diagnosis and immunotherapy
- (2018) Ming Chen et al. Journal of Translational Medicine
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
- (2018) Jacqulyne P. Robichaux et al. NATURE MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles
- (2018) Takahiro Nakagomi et al. Oncotarget
- Inhibiting TRK Proteins in Clinical Cancer Therapy
- (2018) Allison Lange et al. Cancers
- Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting
- (2018) Carolyn J. Presley et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
- (2018) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.
- (2018) D. Ross Camidge et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).
- (2018) Atsushi Nakamura et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel gene mutations in well-differentiated fetal adenocarcinoma of the lung in the next generation sequencing era
- (2018) Yiyun Fu et al. LUNG CANCER
- Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
- (2018) Nicolas Coudray et al. NATURE MEDICINE
- Diagnosis of NUT carcinoma of lung origin by next-generation sequencing: case report and review of the literature
- (2018) Naiquan Mao et al. CANCER BIOLOGY & THERAPY
- Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
- (2017) June-Koo Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- PS04.06 GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR wt, MET-dysregulated Advanced NSCLC
- (2017) J. Wolf et al. Journal of Thoracic Oncology
- Scientific Advances in Thoracic Oncology 2016
- (2017) Ross A. Soo et al. Journal of Thoracic Oncology
- Responses to Crizotinib Can Occur in High-Level MET -Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations
- (2017) Rafael Caparica et al. Journal of Thoracic Oncology
- Combination Osimertinib and Gefitinib in C797S and T790M EGFR- Mutated Non–Small Cell Lung Cancer
- (2017) Surein Arulananda et al. Journal of Thoracic Oncology
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
- (2017) Charles M Rudin et al. LANCET ONCOLOGY
- Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data
- (2017) Fenghao Sun et al. Molecular Medicine Reports
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathologic and genetic features of primary bronchopulmonary mucoepidermoid carcinoma: the MD Anderson Cancer Center experience and comprehensive review of the literature
- (2017) Alireza Salem et al. VIRCHOWS ARCHIV
- A molecular signature of lung cancer: potential biomarkers for adenocarcinoma and squamous cell carcinoma
- (2017) Varda Shoshan-Barmatz et al. Oncotarget
- Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
- (2017) Kiyotaka Yoh et al. Lancet Respiratory Medicine
- Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
- (2016) V. Velcheti et al. ANNALS OF ONCOLOGY
- Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung
- (2016) Tomohiro Miyoshi et al. CLINICAL CANCER RESEARCH
- Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets
- (2016) N. Rekhtman et al. CLINICAL CANCER RESEARCH
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role forTERT,RB1,MEN1andKMT2D
- (2016) Michele Simbolo et al. JOURNAL OF PATHOLOGY
- Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung
- (2016) Luisella Righi et al. Journal of Thoracic Oncology
- KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung
- (2016) David H. Hwang et al. Journal of Thoracic Oncology
- Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations
- (2016) Yan Zhang et al. Journal of Thoracic Oncology
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases
- (2016) Simone BSP Terra et al. MODERN PATHOLOGY
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
- (2016) Joshua D Campbell et al. NATURE GENETICS
- A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features
- (2016) Jianya Zhou et al. PLoS One
- Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features
- (2016) Kun-Hsing Yu et al. Nature Communications
- Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing
- (2016) Ye Wang et al. Oncotarget
- Pulmonary Adenocarcinoma With Enteric Differentiation
- (2016) Alessia Nottegar et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors
- (2016) Robert Fred Henry Walter et al. Journal of Cancer
- High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets
- (2015) V. Fallet et al. ANNALS OF ONCOLOGY
- Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer
- (2015) A. Song et al. CLINICAL CANCER RESEARCH
- Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma
- (2015) Zhen Huo et al. Diagnostic Pathology
- High-grade fetal adenocarcinoma of the lung is a tumour with a fetal phenotype that shows diverse differentiation, including high-grade neuroendocrine carcinoma: a clinicopathological, immunohistochemical and mutational study of 20 cases
- (2015) Masaki Suzuki et al. HISTOPATHOLOGY
- NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas
- (2015) Lydia Meder et al. INTERNATIONAL JOURNAL OF CANCER
- Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung
- (2015) Hyo Sup Shim et al. Journal of Thoracic Oncology
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Driver Gene Mutations of Non-Small-Cell Lung Cancer are Rare in Primary Carcinoids of the Lung: NGS Study by Ion Torrent
- (2015) Gemma Armengol et al. LUNG
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- Identification of MicroRNAs Differentially Expressed in Lung Carcinoid Subtypes and Progression
- (2015) Ida Rapa et al. NEUROENDOCRINOLOGY
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
- (2015) Matthew J. Niederst et al. Nature Communications
- Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
- (2015) P. K. Paik et al. Cancer Discovery
- Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma
- (2014) Kyuichi Kadota et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
- (2014) T. Nakaoku et al. CLINICAL CANCER RESEARCH
- A MicroRNA Cluster at 14q32 Drives Aggressive Lung Adenocarcinoma
- (2014) E. Nadal et al. CLINICAL CANCER RESEARCH
- Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- CLCA2 as a Novel Immunohistochemical Marker for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung
- (2014) Kazuya Shinmura et al. DISEASE MARKERS
- Analysis of Major Known Driver Mutations and Prognosis in Resected Adenosquamous Lung Carcinomas
- (2014) Rui Wang et al. Journal of Thoracic Oncology
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
- (2014) Yuankai Shi et al. Journal of Thoracic Oncology
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Histopathologic, immunophenotypic and cytogenetic features of pulmonary mucoepidermoid carcinoma
- (2014) Anja C Roden et al. MODERN PATHOLOGY
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy
- (2014) Jinbiao Shang et al. ONCOLOGY REPORTS
- Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
- (2014) Lynnette Fernandez-Cuesta et al. Nature Communications
- CD74-NRG1 Fusions in Lung Adenocarcinoma
- (2014) L. Fernandez-Cuesta et al. Cancer Discovery
- ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas
- (2013) Lynette M. Sholl et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Pulmonary Large Cell Carcinoma Lacking Squamous Differentiation Is Clinicopathologically Indistinguishable From Solid-Subtype Adenocarcinoma
- (2013) David H. Hwang et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas
- (2013) Muhammad F Bari et al. HISTOPATHOLOGY
- HER2andEGFRgene copy number alterations are predominant in high-grade salivary mucoepidermoid carcinoma irrespective ofMAML2fusion status
- (2013) Takafumi Nakano et al. HISTOPATHOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Neuroendocrine tumours—challenges in the diagnosis and classification of pulmonary neuroendocrine tumours
- (2013) M A den Bakker et al. JOURNAL OF CLINICAL PATHOLOGY
- Transformation to “high grade” neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma
- (2013) S. Popat et al. LUNG CANCER
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma
- (2012) Yongfeng Yu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- KrasG12D and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung
- (2012) Yutaka Maeda et al. JOURNAL OF CLINICAL INVESTIGATION
- RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
- (2012) Rui Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases
- (2011) Akihiko Yoshizawa et al. MODERN PATHOLOGY
- Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas
- (2010) Yih-Leong Chang et al. CANCER SCIENCE
- Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability
- (2010) Michael A den Bakker et al. HISTOPATHOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- Mammalian mastermind like 2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma
- (2009) Rosane De Oliveira Duarte Achcar et al. HUMAN PATHOLOGY
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
- Demystified molecular pathology of NUT midline carcinomas
- (2008) C. A. French JOURNAL OF CLINICAL PATHOLOGY
- EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
- (2008) Kentaro Inamura et al. Journal of Thoracic Oncology
- Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment
- (2008) Sae-Won Han et al. LUNG CANCER
- Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis
- (2008) Giulio Rossi et al. LUNG CANCER
- Correlation between morphology and EGFR mutations in lung adenocarcinomas
- (2008) Hironori Ninomiya et al. LUNG CANCER
- Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic and mutational analysis study
- (2008) Ricardo S Macarenco et al. MODERN PATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started